Flerie
Flerie is a Stockholm-based life science investment company that owns and develops a portfolio of biotech, pharmaceutical, and related healthcare businesses. Its portfolio is organized around companies in product development and companies in commercial growth, with investments across Europe, Israel, and the United States.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueEarly and mid-stage biotech, pharma, and product companies advancing toward clinical proof-of-concept and approvals.
Companies already selling products or services and scaling market share in life science markets.
Customers
Flerie’s direct counterparties are the founders, management teams, and boards of its portfolio companies rather than end consumers. The underlying portfolio companies serve patients, healthcare providers, and life science customers through drug development, manufacturing, and specialized services. Flerie also serves its own shareholders by providing listed exposure to a diversified life science portfolio.
They receive capital, governance support, and strategic input to advance development and commercialization.
They partner with Flerie in financing rounds and value-creation initiatives across the portfolio.
They are the end beneficiaries of the drugs, diagnostics, and life science solutions developed by portfolio companies.
They buy enabling technologies, tools, or specialized services from commercial growth holdings.
They buy Flerie shares to gain diversified, listed exposure to private life science investing.
Strategy
Flerie’s strategy is active ownership: it takes board representation, works closely with management, and supports key decisions around development, financing, partnerships, and commercialization. The company focuses on life science opportunities where scientific impact, unmet medical need, and commercial potential overlap, while keeping a long-term investment horizon through its evergreen structure.
Direct governance and operational input help portfolio companies progress faster and with clearer strategic direction.
Supporting companies from early research through commercialization increases the chance of capturing long-term value creation.
A broad mandate across modalities and stages helps balance scientific risk and commercial risk.
Geography
Flerie is based in Stockholm and manages a portfolio with exposure to several European markets, Israel, and the United States. Its business is therefore shaped by cross-border portfolio ownership, local regulatory regimes, and access to specialist life science ecosystems in multiple regions.
Risks
Flerie’s main risks come from the valuation and financing characteristics of private life science investing, where outcomes depend on clinical progress, regulatory approvals, and market adoption. The company is also exposed to liquidity, credit, exchange-rate, and reporting risks because it holds a mix of listed and unlisted assets and uses fair-value estimates for a large part of the portfolio.
- Clinical and regulatory failureImpact: CriticalLikelihood: Medium
Product development companies depend on trial success, approvals, and commercialization pathways that may not materialize.
Exposure: Early and mid-stage biotech and pharma holdings
- Valuation risk on private portfolio companiesImpact: HighLikelihood: High
Many holdings are unlisted and valued using judgment-based methods, so changes in assumptions can materially affect reported value.
Exposure: Product Development and Commercial Growth portfolios
- Liquidity and financing riskImpact: HighLikelihood: Low
Portfolio companies may require follow-on capital, while Flerie must manage its own funding and investment commitments.
Exposure: Investment commitments and portfolio support
- Foreign exchange riskImpact: MediumLikelihood: High
Investments span multiple currencies and jurisdictions, creating translation and transaction exposure.
Exposure - Credit risk on receivables and loan exposuresImpact: MediumLikelihood: Low
The company has financial assets such as loan receivables from portfolio companies that may require impairment assessment.
Exposure: Portfolio financing and other financial assets
Accounting
Judgemental itemsA large share of assets is measured using Level 3 or other non-observable inputs, so valuation changes can materially move reported equity and profit.
Impact: Net asset value and fair value gains/losses
DCF and other bespoke methods depend on assumptions about future cash flows, milestones, and comparables.
Impact: Reported investment carrying values
Loan receivables and other financial assets are subject to impairment assessment under amortized cost accounting.
Impact: Profit and carrying value of financial assets
Right-of-use assets and lease liabilities affect balance sheet presentation and depreciation/interest expense.
Impact: EBITDA, depreciation, and leverage presentation
Taxability depends on whether investments are held for business purposes or are taxable listed holdings.
Impact: Current tax and deferred tax
Similar listed companies
Publicly listed companies with a comparable business focus.
Healthier Choices Management Corp.
HCMC · Tobacco Products
Hong Yuan Holding Group
HGYN · Plastic Materials, Synth Resins & Nonvulcan Elastomers
HONG YUAN HOLDING GROUP is a U.S.-listed company in the plastics and synthetic resins value chain.
Valuence Merger Corp. I
VMCUF · Blank Checks
Valuence Merger Corp.
American Exceptionalism Acquisition Corp. A
AEXA · Blank Checks
American Exceptionalism Acquisition Corp.
Artificial Intelligence Technology Solutions Inc.
AITX · Services-Prepackaged Software
Amgen Inc
AMGN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026